Biosciences
Offspring
Your Partner in Therapeutic Antibody Development
Accelerating Antibody Drug Development with Precision Tissue Insights
Human Tissue Insights
Comprehensive analysis of antibody binding properties, on/off target engagement and biomarker expression in human tissues (both normal and disease).
Proven Track Record
A specialized CRO since 2012. Offspring Biosciences supports pharmaceutical and biotech companies with advanced tissue-based analytics to accelerate drug development.
Pharma background
Our team brings extensive experience from AstraZeneca, combining deep industry knowledge with cutting-edge molecular pathology techniques.
Tailored solutions
We offer flexible, customized services to overcome challenges in antibody drug development, enhacing clinical success rates.
From Discovery to Clinical Success: Our tiered Service Offering
Target validation
Hit/Lead ID
Lead Opt
Preclin Dev
Clin Dev
Service Module 1 Target Validation
Pharma Challenge
-
Late-stage failures due to poorly validated targets
-
Difficulty in assessing target expression in disease-relevant contexts
Offspring Solution
-
Comprehensive analysis of target expression and biomarkers for target activity and pathology in normal and disease-relevant human tissues
Benefits
-
Enhances confidence in target selection and prioritization for clinical success
-
Reduces late-stage failures by ensuring robust early validation
Service Module 2 Hit / Lead Identification
Pharma Challenge
-
Early identification of promising antibody candidates
-
Risk of selecting suboptimal leads due to insufficient early-stage data
Offspring Solution
-
Rapid screening of 10 - 100 candidates using immunohistochemistry (IHC) on small set of human tissues, fixed protocol
Benefits
-
Accelerates identification of Lead antibodies with desired on/off target binding properties
Service Module 3 Lead Optimization
Pharma Challenge
-
Suboptimal developability of antibody candidates (eg poor affinity, specificity, solubility)
Offspring Solution
-
Supporting iterative cycles of structure-based optimization, guided by IHC analysis on expanded set of human tissues, 3-5 selected antibodies
Benefits
-
Improved demonstration of specificity and affinity with relevant clinical endpoints
Service Module 4 Preclinical Development
Pharma Challenge
-
Attrition due to lack of poor PK/PD properties, target engagement, unclear mechanisms of action and off target binding
Offspring Solution
-
Demonstrating target engagement in situ and in vivo in native tissues
-
Evaluating antibody PK and PD properties in the context of of biomarker for mechanism and effect
-
Tissue cross reactivity studies in human tissue
Benefits
-
Improved demonstration of target engagement and efficacy. Reduced risk for attrition due to safety
Service Module 5 Clinical Development
Pharma Challenge
-
Ineffective patient selection
-
Lack of informative biomarker assays for assessement of mechanism, efficacy and side effects
Offspring Solution
-
Analysing target expression and regulation as well as antibody binding profile in larger cohorts of human diseased tissue
-
Supporting development of biomarker assays (mechanism and clinical efficacy)
Benefits
-
Improved trial success rates
-
Robust regulatory submissions
Testimonials
Moa Fransson
PhD, CEO at Genagon Therapeutics AB
Genagon Therapeutics characterize novel targets within immuno-oncology and develop first in class therapeutic antibodies. In close dialogue, Offspring delivered a relevant assay design, for a previously uncharacterized protein, together with an exceptional characterization of cell-based immunological markers on quality-controlled tissue samples, aiding us to determine the biological relevance of our target. We have gained important knowledge regarding our target biology, a most important piece in our pre-clinical program.
Johanna Fälting
Chief R&D Officer, Head of Research & Development at BioArctic AB
We have worked with Offspring for several years and have always been impressed by the quality in their deliveries. Also the engagement they show in our projects and what we want to achieve as a company. We can highly recommend them to anyone looking for a first class CRO.
Jonas Ekblom
CEO at Promore Pharma AB
Promore Pharma highly recommends Offspring Biosciences as a provider of services in advanced histopathology analysis. We collaborated with Offspring Biosciences on a project of large scope involving analysis of samples from a Phase II clinical trial. Their state-of-the-art facilities ensured top-notch quality. Their sense of urgency and rapid protocol adaptions were impressive, which resulted in on-time delivery of a complex operation. Moreover, their flexibility and effective meeting management ensured a seamless collaboration. In summary, Offspring offered a perfect match for our unique needs, and consequently, we would wholeheartedly recommend Offspring Biosciences as a service partner.